Kirill V Kosilov1, Sergay A Loparev2, Marina A Ivanovskaya3, Liliya V Kosilova4. 1. Department of Adaptive Medicine, Humanities Institute of Social Sciences, Far Eastern Federal University, Ayax 10, corp. F-733, Vladivostok, Russian Federation. 2. Department of Urology, City Polyclinic No. 3, Vladivostok, Russian Federation. 3. Far Eastern Fisheries University, Vladivostok, Russian Federation. 4. Department of the Functional Methods of Examination, Medical Association No. 2 of Vladivostok-sity, Vladivostok, Russian Federation.
Abstract
OBJECTIVES: The aim of the study was to increase the efficiency of treatment for severe symptoms of overactive bladder (OAB) with antimuscarinic drugs in elderly men and women. METHODS: A total of 341 patients over 65 years of age (average age 69.9; 186 women and 155 men) with severe symptoms of OAB (frequency of incontinence episodes [IEs] ≥ 3/day) underwent examination. Patients were distributed into three main groups: A (n = 58; trospium 60 mg/day + solifenacin 20): three cycles, each cycle 8 weeks, with an 8-week interval; B (n = 55; trospium 30 mg/day + solifenacin 10), regimen was the same as in group A; C (n = 62; trospium 30 mg/day + solifenacin 10) daily during 1 year. RESULTS: The most successful treatment for the clinical and urodynamic symptoms of OAB was observed in group A, without an increase in the quantity or intensity of side effects (IEs = 4.8 (0.9) → 1.4 (0.8); p ≤ 0.01). Groups B and C also demonstrated positive effects for most of the markers for lower urinary tract state with statistical significance p ≤ 0.01. Nonparametric correlation between decrease in IEs and relative number of patients who accurately fulfilled prescriptions was in group A, r = 0.53, p ≤ 0.05; in group B, r = 0.61; p ≤ 0.05; in group C, r = 0.55, p ≤ 0.05. CONCLUSIONS: Cyclic therapy with two different spectrum antimuscarinics appears to be effective for controlling severe OAB in elderly patients. One-year cyclic therapy with a trospium and solifenacin combination provides a high compliance level (76-84%). However, continuous therapy with standard doses of trospium and solifenacin results in low adherence and high rates of treatment withdrawals (≥ 66%) despite satisfactory clinical and urodynamic results.
RCT Entities:
OBJECTIVES: The aim of the study was to increase the efficiency of treatment for severe symptoms of overactive bladder (OAB) with antimuscarinic drugs in elderly men and women. METHODS: A total of 341 patients over 65 years of age (average age 69.9; 186 women and 155 men) with severe symptoms of OAB (frequency of incontinence episodes [IEs] ≥ 3/day) underwent examination. Patients were distributed into three main groups: A (n = 58; trospium 60 mg/day + solifenacin 20): three cycles, each cycle 8 weeks, with an 8-week interval; B (n = 55; trospium 30 mg/day + solifenacin 10), regimen was the same as in group A; C (n = 62; trospium 30 mg/day + solifenacin 10) daily during 1 year. RESULTS: The most successful treatment for the clinical and urodynamic symptoms of OAB was observed in group A, without an increase in the quantity or intensity of side effects (IEs = 4.8 (0.9) → 1.4 (0.8); p ≤ 0.01). Groups B and C also demonstrated positive effects for most of the markers for lower urinary tract state with statistical significance p ≤ 0.01. Nonparametric correlation between decrease in IEs and relative number of patients who accurately fulfilled prescriptions was in group A, r = 0.53, p ≤ 0.05; in group B, r = 0.61; p ≤ 0.05; in group C, r = 0.55, p ≤ 0.05. CONCLUSIONS: Cyclic therapy with two different spectrum antimuscarinics appears to be effective for controlling severe OAB in elderly patients. One-year cyclic therapy with a trospium and solifenacin combination provides a high compliance level (76-84%). However, continuous therapy with standard doses of trospium and solifenacin results in low adherence and high rates of treatment withdrawals (≥ 66%) despite satisfactory clinical and urodynamic results.
Authors: Christopher R Chapple; Linda Cardozo; Victor W Nitti; Emad Siddiqui; Martin C Michel Journal: Neurourol Urodyn Date: 2013-10-11 Impact factor: 2.696
Authors: Chris C Sexton; Karin S Coyne; Christine Thompson; Tamara Bavendam; Chieh-I Chen; Alayne Markland Journal: J Am Geriatr Soc Date: 2011-06-30 Impact factor: 5.562
Authors: Jennifer M Wu; Rebekah G Fulton; Cindy L Amundsen; Sharon K Knight; Miriam Kuppermann Journal: Female Pelvic Med Reconstr Surg Date: 2011-07 Impact factor: 2.091
Authors: Kirill V Kosilov; Sergay A Loparev; Irina G Kuzina; Olga V Shakirova; Yuliya I Gainullina; Liliya V Kosilova; Alexandra S Prokofyeva Journal: Arab J Urol Date: 2017-11-16